Clinical and genetic factors influencing cardiovascular risk in patients with familial hypercholesterolemia

Clinical Lipidology

Volumn 5, Issue 2, 2010, Pages 189-197

  Oosterveer, Daniëlla M ^a   Versmissen, Jorie ^a   Schinkel, Arend F L ^a   Langendonk, Janneke G ^a   Mulder, Monique ^a   Sijbrands, Eric J G ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Cardiovascular disease; Coronary heart disease; Familial hypercholesterolemia; Risk factor

Indexed keywords

BILE ACID SEQUESTRANT; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; DALCETRAPIB; ETC 216; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MIPOMERSEN; NICOTINIC ACID; PACTIMIBE; SIMVASTATIN; TORCETRAPIB; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ATHEROSCLEROSIS; BLOOD CLOTTING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CLINICAL FEATURE; CLINICAL TRIAL; DRUG FATALITY; DRUG MECHANISM; DRUG SAFETY; FAMILIAL HYPERCHOLESTEROLEMIA; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOME ANALYSIS; HEART PROTECTION; HEMOSTASIS; HIGH RISK PATIENT; HUMAN; INFLAMMATION; LIPID METABOLISM; LIPID OXIDATION; ONSET AGE; PATIENT COMPLIANCE; PHENOTYPIC VARIATION; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; UNSPECIFIED SIDE EFFECT;

EID: 77950217259     PISSN: 17460875     EISSN: None     Source Type: Journal    
DOI: 10.2217/clp.10.9     Document Type: Review

References (97)

1. Goldstein JL, Brown MS: The LDL receptor. Arterioscler. Thromb. Vasc. Biol. 29(4), 431-438 (2009).
2. Williams RR, Hunt SC, Schumacher MC et al.: Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am. J. Cardiol. 72(2), 171-176 (1993).
3. Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific steering committee on behalf of the Simon Broome Register Group. BMJ 303(6807), 893-896 (1991).
4. Abifadel M, Varret M, Rabes JP et al.: Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nature genetics 34(2), 154-156 (2003).
5. Innerarity TL, Weisgraber KH, Arnold KS et al.: Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding. Proc. Natl Acad. Sci. USA 84(19), 6919-6923 (1987).
6. Skoumas I, Masoura C, Pitsavos C et al.: Evidence that non-lipid cardiovascular risk factors are associated with high prevalence of coronary artery disease in patients with heterozygous familial hypercholesterolemia or familial combined hyperlipidemia. Int. J.Cardiol. 121(2), 178-183 (2007).
7. Jansen AC, Van Aalst-Cohen ES, Tanck MW et al.: The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J. Intern. Med. 256(6), 482-490 (2004).
8. De Sauvage Nolting PR, Defesche JC, Buirma RJ et al.: Prevalence and significance of cardiovascular risk factors in a large cohort of patients with familial hypercholesterolaemia. J. Intern. Med. 253(2), 161-168 (2003).
9. Kramer A, Jansen AC, Van Aalst-Cohen ES, Tanck MW, Kastelein JJ, Zwinderman AH: Relative risk for cardiovascular atherosclerotic events after smoking cessation: 6-9 years excess risk in individuals with familial hypercholesterolemia. BMC Public Health 6, 262 (2006).
10. Neil HA, Seagroatt V, Betteridge DJ et al.: Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia. Heart 90(12), 1431-1437 (2004).
11. Kastelein JJ, Wiegman A, De Groot E: Surrogate markers of atherosclerosis: Impact of statins. Atheroscler. Suppl. 4(1), 31-36 (2003).
12. Ye ZX, Cheng HM, Chiou KR, Charng MJ: Relation of C-reactive protein and carotid intima media thickness in Taiwanese with familial hypercholesterolemia. Am. J. Cardiol. 102(2), 184-187 (2008).
13. Martinez LR, Miname MH, Bortolotto LA et al.: No correlation and low agreement of imaging and inflammatory atherosclerosis' markers in familial hypercholesterolemia. Atherosclerosis 200(1), 83-88 (2008).
14. Ye ZX, Cheng HM, Chiou KR, Huang PH, Lin SJ, Charng MJ: Relation of coronary artery calcium to flow-mediated dilation and C-reactive protein levels in asymptomatic patients with heterozygous familial hypercholesterolemia. Am. J. Cardiol. 100(7), 1119-1123 (2007).
15. Cheng HM, Ye ZX, Chiou KR, Lin SJ, Charng MJ: Vascular stiffness in familial hypercholesterolaemia is associated with C-reactive protein and cholesterol burden. Eur. J. Clin. Invest. 37(3), 197-206 (2007).
16. Matsuda M, Shimomura I, Sata M et al.: Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J. Biol. Chem. 277(40), 37487-37491 (2002).
17. Pischon T, Girman Cj, Hotamisligil GS, Rifai N, Hu FB, Rimm EB: Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291(14), 1730-1737 (2004).
18. Bouhali T, Brisson D, St-Pierre J et al.: Low plasma adiponectin exacerbates the risk of premature coronary artery disease in familial hypercholesterolemia. Atherosclerosis 196(1), 262-269 (2008).
19. Murase T, Okubo M, Amemiya-Kudo M et al.: Impact of markedly elevated serum lipoprotein(a) levels (100 mg/dl) on the risk of coronary heart disease. Metabolism 56(9), 1187-1191 (2007).
20. Holmes DT, Schick BA, Humphries KH, Frohlich J: Lipoprotein(a) is an independent risk factor for cardiovascular disease in heterozygous familial hypercholesterolemia. Clin. Chem. 51(11), 2067-2073 (2005).
21. Dirisamer A, Widhalm H, Aldover-Macasaet E, Molzer S, Widhalm K: Elevated Lp(a) with a small Apo(a) isoform in children: risk factor for the development of premature coronary artery disease. Acta Paediatr. 97(12), 1653-1657 (2008).
22. Makedou A, Kourti M, Makedou K, Lazaridou S, Varlamis G: Lipid profile of children with a family history of coronary heart disease or hyperlipidemia: 9-year experience of an outpatient clinic for the prevention of cardiovascular diseases. Angiology 56(4), 391-395 (2005).
23. Van Der Graaf A, Rodenburg J, Vissers MN et al.: Atherogenic lipoprotein particle size and concentrations and the effect of pravastatin in children with familial hypercholesterolemia. J. Pediatr. 152(6), 873-878 (2008).
24. Van Jaarsveld H, Pool GF, Bester CJ: Composition of LDL particle discriminates between hypercholesterolaemic persons with and without symptoms of coronary heart disease. Ann. Clin. Biochem. 41(Pt 3), 213-219 (2004).
25. Austin MA, King MC, Vranizan KM, Krauss RM: Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 82(2), 495-506 (1990).
26. Van Schalkwijk DB, De Graaf AA, Van Ommen B et al.: Improved cholesterol phenotype analysis by a model relating lipoprotein lifecycle processes to particle size. J. Lipid Res. 50, 2398-2411 (2009).
27. Hogue JC, Lamarche B, Gaudet D et al.: Association of heterozygous familial hypercholesterolemia with smaller HDL particle size. Atherosclerosis 190(2), 429-435 (2007).
28. Balstad TR, Holven KB, Ottestad IO et al.: Altered composition of HDL3 in FH subjects causing a HDL subfraction with less atheroprotective function. Clin. Chim. Acta 359(1-2), 171-178 (2005).
29. Brensike JF, Levy RI, Kelsey SF et al.: Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI type II coronary intervention study. Circulation 69(2), 313-324 (1984).
30. The lipid research clinics coronary primary prevention trial results. I. Reduction in incidence of coronary heart disease. JAMA 251(3), 351-364 (1984).
31. Versmissen J, Oosterveer DM, Yazdanpanah M et al.: Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ 337, A2423 (2008).
32. Neil A, Cooper J, Betteridge J et al.: Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: A prospective registry study. Eur. Heart J. 29(21), 2625-2633 (2008).
33. Kastelein JJ, Akdim F, Stroes ES et al.: Simvastatin with or without ezetimibe in familial hypercholesterolemia. N. Engl. J. Med. 358(14), 1431-1443 (2008).
34. Rizzo M, Rini GB, Spinas GA, Berneis K: The effects of ezetimibe on LDL-cholesterol: quantitative or qualitative changes? Atherosclerosis 204, 330-333 (2009).
35. Alonso R, Mata N, Castillo S et al.: Cardiovascular disease in familial hypercholesterolaemia: influence of low-density lipoprotein receptor mutation type and classic risk factors. Atherosclerosis 200(2), 315-321 (2008).
36. Junyent M, Gilabert R, Zambon D et al.: Femoral atherosclerosis in heterozygous familial hypercholesterolemia: influence of the genetic defect. Arterioscler. Thromb. Vasc. Biol. 28(3), 580-586 (2008).
37. Guardamagna O, Restagno G, Rolfo E et al.: The type of LDLR gene mutation predicts cardiovascular risk in children with familial hypercholesterolemia. J. Pediatr. 155(2), 199-204 (2009).
38. Bertolini S, Cantafora A, Averna M et al.: Clinical expression of familial hypercholesterolemia in clusters of mutations of the LDL receptor gene that cause a receptor-defective or receptor-negative phenotype. Arterioscler. Thromb. Vasc. Biol. 20(9), E41-E52 (2000).
39. Souverein OW, Defesche JC, Zwinderman AH, Kastelein JJ, Tanck MW: Influence of LDL receptor mutation type on age at first cardiovascular event in patients with familial hypercholesterolaemia. Eur. Heart J. 28(3), 299-304 (2007).
40. Koeijvoets KC, Rodenburg J, Hutten BA, Wiegman A, Kastelein JJ, Sijbrands EJ: Low-density lipoprotein receptor genotype and response to pravastatin in children with familial hypercholesterolemia: substudy of an intima-media thickness trial. Circulation 112(20), 3168-3173 (2005).
41. Koeijvoets KC, Wiegman A, Rodenburg J, Defesche JC, Kastelein JJ, Sijbrands EJ: Effect of low-density lipoprotein receptor mutation on lipoproteins and cardiovascular disease risk: a parent-offspring study. Atherosclerosis 180(1), 93-99 (2005).
42. Sijbrands EJ, Westendorp RG, Paola Lombardi M et al.: Additional risk factors influence excess mortality in heterozygous familial hypercholesterolaemia. Atherosclerosis 149(2), 421-425 (2000).
43. Ferrieres J, Lambert J, Lussier-Cacan S, Davignon J: Coronary artery disease in heterozygous familial hypercholesterolemia patients with the same LDL receptor gene mutation. Circulation 92(3), 290-295 (1995).
44. Umans-Eckenhausen MA, Defesche JC, Sijbrands EJ, ScheerDer RL, Kastelein JJ: Review of first 5 years of screening for familial hypercholesterolemia in The Netherlands. Lancet 357(9251), 165-168 (2001).
45. Mozas P, Castillo S, Reyes G et al.: Apolipoprotein E genotype is not associated with cardiovascular disease in heterozygous subjects with familial hypercholesterolemia. Am. Heart J. 145(6), 999-1005 (2003).
46. Jansen AC, Van Aalst-Cohen ES, Tanck MW et al.: Genetic determinants of cardiovascular disease risk in familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 25(7), 1475-1481 (2005).
47. Pitsavos C, Choumerianou DM, Skoumas J et al.: Apolipoprotein E polymorphism is not associated with lipid levels and coronary artery disease in Greek patients with familial hypercholesterolaemia. Clin. Exp. Med. 5(4), 196-201 (2005).
48. Abifadel M, Rabes JP, Jambart S et al.: The molecular basis of familial hypercholesterolemia in Lebanon: spectrum of LDLR mutations and role of PCSK9 as a modifier gene. Hum. Mutat. 30(7), E682-E691 (2009).
49. Mohrschladt MF, Van Der Sman-De Beer F, Hofman MK, Van Der Krabben M, Westendorp RG, Smelt AH: TaqIB polymorphism in CETP gene: the influence on incidence of cardiovascular disease in statin-treated patients with familial hypercholesterolemia. Eur. J. Hum. Genet. 13(7), 877-882 (2005).
50. Cenarro A, Artieda M, Castillo S et al.: A common variant in the ABCA1 gene is associated with a lower risk for premature coronary heart disease in familial hypercholesterolaemia. J. Med. Genet. 40(3), 163-168 (2003).
51. Bertolini S, Pisciotta L, Di Scala L et al.: Genetic polymorphisms affecting the phenotypic expression of familial hypercholesterolemia. Atherosclerosis 174(1), 57-65 (2004).
52. Zwarts KY, Clee SM, Zwinderman AH et al.: ABCA1 regulatory variants influence coronary artery disease independent of effects on plasma lipid levels. Clin. Genet. 61(2), 115-125 (2002).
53. Choumerianou DM, Maumus S, Skoumas J et al.: Polymorphisms associated with apolipoprotein B levels in Greek patients with familial hypercholesterolemia. Clin. Chem. Lab. Med. 44(7), 799-806 (2006).
54. Dedoussis GV, Maumus S, Choumerianou DM et al.: Different genes and polymorphisms affecting high-density lipoprotein cholesterol levels in Greek familial hypercholesterolemia patients. Genet. Test. 10(3), 192-199 (2006).
55. Wittekoek ME, Pimstone SN, Reymer PW et al.: A common mutation in the lipoprotein lipase gene (N291S) alters the lipoprotein phenotype and risk for cardiovascular disease in patients with familial hypercholesterolemia. Circulation 97(8), 729-735 (1998).
56. Wittekoek ME, Moll E, Pimstone SN et al.: A frequent mutation in the lipoprotein lipase gene (D9N) deteriorates the biochemical and clinical phenotype of familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 19(11), 2708-2713 (1999).
57. Koeijvoets KC, Van Der Net JB, Dallinga-Thie GM et al.: ABCG8 gene polymorphisms, plasma cholesterol concentrations, and risk of cardiovascular disease in familial hypercholesterolemia. Atherosclerosis 204(2), 453-458. (2008).
58. Witztum JL, Steinberg D: Role of oxidized low density lipoprotein in atherogenesis. J. Clin. Invest. 88(6), 1785-1792 (1991).
59. Roest M, Rodenburg J, Wiegman A, Kastelein JJ, Voorbij HA: Paraoxonase genotype and carotid intima-media thickness in children with familial hypercholesterolemia. Eur. J. Cardiovasc. Prev. Rehabil. 13(3), 464-466 (2006).
60. Leus FR, Wittekoek ME, Prins J, Kastelein JJ, Voorbij HA: Paraoxonase gene polymorphisms are associated with carotid arterial wall thickness in subjects with familial hypercholesterolemia. Atherosclerosis 149(2), 371-377 (2000).
61. Leus FR, Zwart M, Kastelein JJ, Voorbij HA: PON2 gene variants are associated with clinical manifestations of cardiovascular disease in familial hypercholesterolemia patients. Atherosclerosis 154(3), 641-649 (2001).
62. Roest M, Jansen AC, Barendrecht A, Leus FR, Kastelein JJ, Voorbij HA: Variation at the paraoxonase gene locus contributes to carotid arterial wall thickness in subjects with familial hypercholesterolemia. Clin. Biochem. 38(2), 123-127 (2005).
63. Stokes KY, Cooper D, Tailor A, Granger DN: Hypercholesterolemia promotes inflammation and microvascular dysfunction: role of nitric oxide and superoxide. Free Radic. Biol. Med. 33, 1026-1036 (2002).
64. Bisoendial RJ, Kastelein JJ, Peters SL et al.: Effects of CRP infusion on endothelial function and coagulation in normocholesterolemic and hypercholesterolemic subjects. J. Lipid Res. 48, 952-960 (2007).
65. Van Der Net JB, Versmissen J, Oosterveer DM et al.: Arachidonate 5-lipoxygenase-activating protein (ALOX5AP) gene and coronary heart disease risk in familial hypercholesterolemia. Atherosclerosis 203(2), 472-478 (2009).
66. Koeijvoets KC, Mooijaart SP, Dallinga-Thie GM et al.: Complement factor H Y402H decreases cardiovascular disease risk in patients with familial hypercholesterolaemia. Eur. Heart J. 30(5), 618-623 (2009).
67. Van Der Net JB, Isaacs A, Dallinga-Thie GM et al.: Haplotype of the angiotensinogen gene is associated with coronary heart disease in familial hypercholesterolemia. J. Hypertens. 26(3), 462-467 (2008).
68. Wierzbicki AS, Lambert-Hammill M, Lumb PJ, Crook MA: Renin-angiotensin system polymorphisms and coronary events in familial hypercholesterolemia. Hypertension 36(5), 808-812 (2000).
69. O'Malley JP, Maslen CL, Illingworth DR: Angiotensin-converting enzyme DD genotype and cardiovascular disease in heterozygous familial hypercholesterolemia. Circulation 97(18), 1780-1783 (1998).
70. Hopkins PN, Stephenson S, Wu LL, Riley WA, Xin Y, Hunt SC: Evaluation of coronary risk factors in patients with heterozygous familial hypercholesterolemia. Am. J. Cardiol. 87(5), 547-553 (2001).
71. Van Der Net JB, Van Etten J, Yazdanpanah M et al.: Gene-load score of the renin-angiotensin-aldosterone system is associated with coronary heart disease in familial hypercholesterolaemia. Eur. Heart J. 29(11), 1370-1376 (2008).
72. Cenarro A, Casao E, Civeira F, Jensen HK, Faergeman O, Pocovi M: P1A1/A2 polymorphism of platelet glycoprotein IIIa and risk of acute coronary syndromes in heterozygous familial hypercholesterolemia. Atherosclerosis 143(1), 99-104 (1999).
73. Koeijvoets KC, Van Der Net JB, Van Rossum EF et al.: Two common haplotypes of the glucocorticoid receptor gene are associated with increased susceptibility to cardiovascular disease in men with familial hypercholesterolemia. J. Clin. Endocrinol. Metab. 93(12), 4902-4908 (2008).
74. Lu H, Higashikata T, Inazu A et al.: Association of estrogen receptor-a gene polymorphisms with coronary artery disease in patients with familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 22(5), 817-823 (2002).
75. Kawashiri M, Kajinami K, Nohara A et al.: Effect of common methylenetetrahydrofolate reductase gene mutation on coronary artery disease in familial hypercholesterolemia. Am. J. Cardiol. 86(8), 840-845 (2000).
76. Dedoussis GV, Maumus S, Skoumas J et al.: Natriuretic peptide val7met substitution and risk of coronary artery disease in Greek patients with familial hypercholesterolemia. J. Clin. Lab. Anal. 20(3), 98-104 (2006).
77. Van Der Net JB, Oosterveer DM, Versmissen J et al.: Replication study of 10 genetic polymorphisms associated with coronary heart disease in a specific high-risk population with familial hypercholesterolemia. Eur. Heart J. 29(18), 2195-2201 (2008).
78. Van Der Net JB, Janssens AC, Defesche JC, Kastelein JJ, Sijbrands EJ, Steyerberg EW: Usefulness of genetic polymorphisms and conventional risk factors to predict coronary heart disease in patients with familial hypercholesterolemia. Am. J. Cardiol. 103(3), 375-380 (2009).
79. Alonso R, Fernandez De Bobadilla J, Mendez I, Lazaro P, Mata N, Mata P: Cost-effectiveness of managing familial hypercholesterolemia using atorvastatin-based preventive therapy. Rev. Esp. Cardiol. 61(4), 382-393 (2008).
80. Seiki S, Frishman WH: Pharmacologic inhibition of squalene synthase and other downstream enzymes of the cholesterol synthesis pathway: a new therapeutic approach to treatment of hypercholesterolemia. Cardiol. Rev. 17(2), 70-76 (2009).
81. Khoo B, Krainer AR: Splicing therapeutics in SMN2 and APOB. Curr. Opin. Mol. Ther. 11(2), 108-115 (2009).
82. Cao G, Qian YW, Kowala MC, Konrad RJ: Further LDL cholesterol lowering through targeting PCSK9 for coronary artery disease. Endocr. Metab. Immune Disord. Drug Targets 8(4), 238-243 (2008).
83. Kastelein JJ, Wedel MK, Baker BF: Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 114(16), 1729-1735 (2006).
84. Meuwese MC, De Groot E, Duivenvoorden R et al.: ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: the captivate randomized trial. JAMA 301(11), 1131-1139 (2009).
85. Kastelein JJ, Van Leuven SI, Burgess L et al.: Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N. Engl. J. Med. 356(16), 1620-1630 (2007).
86. Roglans N, Verd JC, Peris et al.: High doses of atorvastatin and simvastatin induce key enzymes involved in VLDL production. Lipids 37(5), 445-454 (2002).
87. De Haan W, Van Der Hoogt CC, Westerterp M et al.: Atorvastatin increases HDL cholesterol by reducing CETP expression in cholesterol-fed ApoE*3-Leiden CETP mice. Atherosclerosis 197(1), 57-63 (2008).
88. Schwartz GG, Olsson AG, Ballantyne CM et al.: Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am. Heart J. 158(6), 896-901 E3(2009).
89. Montecucco F, Mach F: Update on statin-mediated anti-inflammatory activities in atherosclerosis. Semin. Immunopathol. 31(1), 127-142 (2009).
90. Libby P, Aikawa M: Effects of statins in reducing thrombotic risk and modulating plaque vulnerability. Clin, Cardiol. 26(1 Suppl. 1), I11-I14 (2003).
91. Golomb BA, Dimsdale JE, White HL, Ritchie JB, Criqui MH: Reduction in blood pressure with statins: Results from the UCSD statin study, a randomized trial. Arch. Intern. Med. 168(7), 721-727 (2008).
92. Feldstein CA: Statins in hypertension: are they a new class of antihypertensive agents? Am. J. Ther. DOI: 10.1097/MJT.0b013e3181c0695e (2009) (Epub ahead of print).
93. Taylor AJ, Villines TC, Stanke EJ et al.: Extended-release niacin or ezetimibe and carotid intima-media thickness. N. Engl. J. Med. 361(22), 2113-2122 (2009).
94. Guyton JR, Brown BG, Fazio S, Polis A, Tomassini JE, Tershakovec AM: Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministrated with extended-release niacin in patients with type IIa or type IIb hyperlipidemia. J. Am. Coll. Cadiol. 51(16), 1564-1572 (2008).
95. Nissen SE, Tsunoda T, Tuzcu EM et al.: Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 290(17), 2292-2300 (2003).
96. Navab M, Schechter I, Anantharamiaiah GM, Reddy ST, Van Lenten BJ, Fogelman AM: Structure and function of HDL mimetics. Arterioscler. Thromb. Vasc. Biol. 30(2), 164-168 (2009)
97. Thaxton CS, Daniel WL, Giljohann DA, Thomas AD, Mirkin CA: Templated spherical high density lipoprotein nanoparticles. J. Am. Chem. Soc. 131(4), 1384-1385 (2009).